Evidence map›Paper›PMID 33866396›Full record

ArticleAnnals of hematology2021

Long-term outcome after allogeneic stem cell transplantation in multiple myeloma.

Sini Luoma, Raija Silvennoinen, Auvo Rauhala, Riitta Niittyvuopio, Eeva Martelin, Vesa Lindström, Jouni Heiskanen, Liisa Volin, Tapani Ruutu, Anne Nihtinen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sini LuomaComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland. sini.luoma@gmail.com.ORCID http://orcid.org/0000-0002-1194-7027
Raija SilvennoinenComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Auvo RauhalaFaculty of Education and Welfare Studies, Åbo Akademi University, Vaasa, Finland.
Riitta NiittyvuopioComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Eeva MartelinComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Vesa LindströmComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Jouni HeiskanenComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Liisa VolinComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Tapani RuutuComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
Anne NihtinenComprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 372, 00290, Helsinki, Finland.
University of Helsinki · FIÅbo Akademi University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of allogeneic hematopoietic stem cell transplantation (allo-SCT) in multiple myeloma is controversial. We analyzed the results of 205 patients transplanted in one center during 2000-2017. Transplantation was performed on 75 patients without a previous autologous SCT (upfront-allo), on 74 as tandem transplant (auto-allo), and on 56 patients after relapse. Median overall survival (OS) was 9.9 years for upfront-allo, 11.2 years for auto-allo, and 3.9 years for the relapse group (p = 0.015). Progression-free survival (PFS) was 2.4, 2.4, and 0.9 years, respectively (p < 0.001). Non-relapse mortality at 5 years was 8% overall, with no significant difference between the groups. Post-relapse survival was 4.1 years for upfront-allo and auto-allo, and 2.6 years for the relapse group (p = 0.066). Survival of high-risk patients was reduced. In multivariate analysis, the auto-allo group had improved OS and chronic graft-versus-host disease was advantageous in terms of PFS, OS, and relapse incidence. Late relapses occurred in all groups. Allo-SCT resulted in long-term survival in a small subgroup of patients. Our results indicate that auto-allo-SCT is feasible and could be considered for younger patients in the upfront setting.

Indexed as

Hematopoietic Stem Cell TransplantationFemaleHumansMaleMiddle AgedMultiple MyelomaNeoplasm Recurrence, LocalProgression-Free SurvivalTransplantation, HomologousTreatment OutcomeAllogeneic stem cell transplantationConditioningGraft-versus-host diseaseMultiple myelomaPost-relapse survivalSurvival

Identifiers

PMID33866396
PMCPMC8116307
OpenAlexW3154726226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.